Anika Therapeutics (ANIK) – StreetInsider.com Reports
-
Anika Therapeutics (ANIK) Tops Q4 EPS by 28c ; Offers Guidance
-
Anika Therapeutics (ANIK) Announces Retirement of Jeffery S. Thompson from Board
-
Anika Therapeutics (ANIK) Tops Q3 EPS by 35c
-
Anika Therapeutics (ANIK) Announces the Full Market Release of the RevoMotion Reverse Shoulder Arthroplasty System
-
Blackstone (BX), Airbnb (ABNB) to Join S&P 500
-
Barrington Research Upgrades Anika Therapeutics (ANIK) to Outperform
-
Anika Therapeutics (ANIK) PT Lowered to $23 at Stephens
-
Anika Therapeutics (ANIK) PT Lowered to $32 at Sidoti
-
Anika Therapeutics (ANIK) Tops Q2 EPS by 38c ; Offers Guidance
-
Anika Therapeutics (ANIK) completes enrollment in Phase III clinical study for Hyalofast
-
Anika Therapeutics (ANIK) Tops Q1 EPS by 13c
-
Anika Therapeutics (ANIK) Enters Into Cooperation Agreement with Caligan Partners
-
Anika Therapeutics (ANIK) Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA
-
Anika Therapeutics (ANIK) Files Preliminary Proxy Statement
-
Anika Therapeutics (ANIK) Downgraded to Market Perform at Barrington Research
-
Anika Therapeutics (ANIK) Misses Q4 EPS by 10c
-
Anika Therapeutics (ANIK) Issues Statement
-
Barrington Research Upgrades Anika Therapeutics (ANIK) to Outperform
-
Anika's (ANIK) Cingal Achieves Primary Endpoint in Third Phase III Study
-
Stephens Resumes Anika Therapeutics (ANIK) at Equal Weight
-
Anika Therapeutics (ANIK) Tops Q2 EPS by 11c
-
Anika Therapeutics (ANIK) Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio
-
Companies with NDRs 3/17
-
Barrington Research Downgrades Anika Therapeutics (ANIK) to Market Perform
-
Stephens Downgrades Anika Therapeutics (ANIK) to Equal Weight
-
Anika Therapeutics (ANIK) Management Event Takeaways - UBS
-
UPDATE: Stephens Starts Anika Therapeutics (ANIK) at Overweight
-
Anika Therapeutics (ANIK) Appoints Sheryl Conley to its Board
-
Anika Therapeutics (ANIK) Receives Additional 510(k) FDA Clearance for Tactoset® Injectable Bone Substitute
-
UBS Starts Anika Therapeutics (ANIK) at Neutral
-
Anika Therapeutics (ANIK) PT Raised to $59 at Sidoti
-
Anika Therapeutics (ANIK) PT Raised to $61 at Sidoti
-
Barrington Research Upgrades Anika Therapeutics (ANIK) to Outperform
-
Anika Therapeutics (ANIK) Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints
-
Anika Therapeutics (ANIK) Announces Launch of Six FDA-Cleared Sports Medicine and Extremities Products in 3Q20
-
Anika Therapeutics (ANIK) Announces Planned CFO Transition
-
Barrington Research Downgrades Anika Therapeutics (ANIk) to Market Perform
-
Anika Therapeutics (ANIK) Tops Q1 EPS
-
Anika Therapeutics (ANIK) Announces Cheryl R. Blanchard, Ph.D., as President and CEO
-
Anika Therapeutics (ANIK) Takes Actions to Strengthen Liquidity in Light of COVID-19
-
UPDATE: Anika Therapeutics (ANIK) Announces Board Member Dr. Cheryl Blanchard as Interim CEO
-
Anika Therapeutics (ANIK) CEO Joseph Darling Unexpectedly Died
-
Anika Therapeutics (ANIK) Halted, News Pending
-
Sidoti Upgrades Anika Therapeutics (ANIK) to Buy
-
First Analysis Upgrades Anika Therapeutics (ANIk) to Strong Buy
-
Anika Therapeutics (ANIK) to Acquire Parcus Medical and Arthrosurface
-
Companies with NDRs 11/12
-
UPDATE: BWS Financial Starts Anika Therapeutics (ANIK) at Sell
-
Anika Therapeutics (ANIK) PT Raised to $50 at Sidoti
-
Anika Therapeutics (ANIK) Tops Q3 EPS by 25c
Back to ANIK Stock Lookup